NOTCH2 as a Survival Marker in Brain Tumors
Author Information
Author(s): Boulay Jean-Louis, Miserez André R., Zweifel Christian, Sivasankaran Balasubramanian, Kana Veronika, Ghaffari Anthony, Luyken Cordelia, Sabel Michael, Zerrouqi Abdessamad, Wasner Morten, Meir Erwin Van, Tolnay Markus, Reifenberger Guido, Merlo Adrian
Primary Institution: University Hospital, Basel, Switzerland
Hypothesis
Does the loss of NOTCH2 predict survival in glioma patients?
Conclusion
Loss of NOTCH2 is associated with better survival in certain subgroups of glioma patients.
Supporting Evidence
- 81% of oligodendroglioma patients showed loss of heterozygosity on chromosome 1p.
- The N2/N2N test distinguished oligodendrogliomas from glioblastomas with high accuracy.
- Centromeric deletions in glioblastomas were linked to better survival outcomes.
Takeaway
If a part of a gene called NOTCH2 is missing, some brain tumor patients might live longer.
Methodology
Somatic deletion mapping was performed on tumor samples to analyze genetic alterations.
Limitations
The study had a low frequency of tumors with 1p centromeric loss, which may limit the generalizability of the findings.
Participant Demographics
The study included 144 glioma patients, with a mix of oligodendrogliomas and glioblastomas.
Statistical Information
P-Value
0.0007
Statistical Significance
p=0.0007
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website